Adverse Prognostic Impact of the KIT D816V Transcriptional Activity in Advanced Systemic Mastocytosis
Authors:
- Nicole NaumannNicole Naumann
- Johannes LübkeJohannes Lübke
- Sofie BaumannSofie Baumann
- Juliana SchwaabJuliana Schwaab
- Oliver HoffmannOliver Hoffmann
- Sebastian KreilSebastian Kreil
- Vito DangeloVito Dangelo
- Lukas ReiterLukas Reiter
- Peter BugertPeter Bugert
- Thomas KristensenThomas Kristensen
- Karl SotlarKarl Sotlar
- Verena HaselmannVerena Haselmann
Open Access
- 4 March 2021
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (5) , 2562
Abstract
In systemic mastocytosis (SM), qualitative and serial quantitative assessment of the KIT D816V mutation is of diagnostic and prognostic relevance. We investigated peripheral blood and bone marrow samples of 161 patients (indolent SM (ISM), n = 40; advanced SM, AdvSM, n = 121) at referral and during follow-up for the KIT D816V variant allele frequency (VAF) at the DNA-level and the KIT D816V expressed allele burden (EAB) at the RNA-level. A round robin test with four participating laboratories revealed an excellent correlation (r > 0.99, R2 > 0.98) between three different DNA-assays. VAF and EAB strongly correlated in ISM (r = 0.91, coefficient of determination, R2 = 0.84) but only to a lesser extent in AdvSM (r = 0.71; R2 = 0.5). However, as compared to an EAB/VAF ratio ≤2 (cohort A, 77/121 patients, 64%) receiver operating characteristic (ROC) analysis identified an EAB/VAF ratio of >2 (cohort B, 44/121 patients, 36%) as predictive for an advanced phenotype and a significantly inferior median survival (3.3 vs. 11.7 years; p = 0.005). In terms of overall survival, Cox-regression analysis was only significant for the EAB/VAF ratio >2 (p = 0.006) but not for VAF or EAB individually. This study demonstrates for the first time that the transcriptional activity of KIT D816V may play an important role in the pathophysiology of SM.Keywords
Funding Information
- José Carreras Leukämie-Stiftung (DJCLS 01R/2018 and DJCLS-08R/2020)
This publication has 23 references indexed in Scilit:
- The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemiaBlood, 2016
- Comparison of gDNA‐based versus mRNA‐based KIT D816V mutation analysis reveals large differences between blood and bone marrow in systemic mastocytosisBritish Journal of Haematology, 2016
- Additional mutations in SRSF2, ASXL1 and/or RUNX1 identify a high-risk group of patients with KIT D816V+ advanced systemic mastocytosisLeukemia, 2015
- The impact of sensitive KIT D816V detection on recognition of Indolent Systemic MastocytosisLeukemia Research, 2015
- The KITD816V allele burden predicts survival in patients with mastocytosis and correlates with the WHO type of the diseaseAllergy, 2014
- The KIT D816V expressed allele burden for diagnosis and disease monitoring of systemic mastocytosisAnnals of Hematology, 2013
- A highly specific q-RT-PCR assay to address the relevance of the JAK2WT and JAK2V617F expression levels and control genes in Ph-negative myeloproliferative neoplasmsAnnals of Hematology, 2013
- Allelic Expression Imbalance of JAK2 V617F Mutation in BCR-ABL Negative Myeloproliferative NeoplasmsPLOS ONE, 2013
- Improved Detection of the KIT D816V Mutation in Patients with Systemic Mastocytosis Using a Quantitative and Highly Sensitive Real-Time qPCR AssayThe Journal of Molecular Diagnostics, 2011
- Limit of blank, limit of detection and limit of quantitation.2008